Beyond folate antagonism: the unique pharmacological blueprint of methotrexate
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20254171Keywords:
Methotrexate, Pharmacokinetics, Pharmacology, Genetic polymorphism, Antirheumatic agentsAbstract
Methotrexate (MTX) possesses a uniquely complex pharmacological profile characterized by nonlinear pharmacokinetics, saturable absorption, transporter-dependent distribution, and intracellular polyglutamation, all of which contribute to substantial interindividual variability in therapeutic response and toxicity. This review summarizes current evidence on MTX absorption kinetics, dose-dependent oral bioavailability, and the role of renal and hepatic pathways in systemic clearance. Special emphasis is placed on the formation and accumulation of MTX polyglutamates (MTX-PGs), which act as long-acting intracellular metabolites that enhance therapeutic duration but may also increase the risk of adverse effects when present at higher concentrations. Genetic polymorphisms in key enzymes and transporters, including RFC1, FPGS, GGH, and members of the SLCO and ABC transporter families, significantly influence MTX disposition, efficacy, and toxicity, underscoring the expanding role of pharmacogenomics in individualized therapy. The review also highlights the relevance of routine laboratory monitoring, emerging biomarkers, and clinical dosing strategies, including split dosing and subcutaneous administration to optimize outcomes across oncology and autoimmune settings. By integrating current pharmacokinetic, pharmacodynamic, and pharmacogenomic insights, this work provides a comprehensive understanding of MTX’s therapeutic behaviour and supports the need for personalized approaches to maximize efficacy while minimizing adverse effects.
Metrics
References
Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;308(18):1094-104. DOI: https://doi.org/10.1056/NEJM198311033091805
Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972-8. DOI: https://doi.org/10.1200/JCO.2008.20.4156
O'Rielly DD, Rahman P. Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med. 2010;3:15-31. DOI: https://doi.org/10.2147/PGPM.S5012
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703. DOI: https://doi.org/10.1634/theoncologist.11-6-694
Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16-25.
Chan ES, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol. 2010;6(3):175-8. DOI: https://doi.org/10.1038/nrrheum.2010.5
Hoekstra M, Haagsma CJ, Neef C, Proost JH, Kadir AA, van de Laar MA. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645-8.
Baggott JE, Morgan SL. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum. 2009;60(8):2257-61. DOI: https://doi.org/10.1002/art.24685
Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489-503. DOI: https://doi.org/10.1111/j.1365-2141.2009.07765.x
Katchamart W, Bourré-Tessier J, Donka T, Drouin J, Rohekar S, et al. Canadian recommendations for pharmacogenomics testing in rheumatology. Arthritis Care Res. 2018;70(5):687-92.
Alarcon GS, Tracy IC, Strand GM. Methotrexate in rheumatoid arthritis. J Rheumatol. 1989;16(19):15-7.
Drugs.com. Available at: https://www.drugs.com/dosage/methotrexate.html#Usual_Adult_Dose_for_Acute_Lymphoblastic_Leukemia. Accessed on 10 June 2025.
Patil VM, Noronha V, Joshi A, Dhumal S, Mahimkar M, Mahajan A, et al. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. J Clin Oncol. 2019;37(32):3032-41. DOI: https://doi.org/10.1200/JCO.19.01076
Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2006;17(2):232-8. DOI: https://doi.org/10.1093/annonc/mdj066
Harsh KK, Maharia SR, Nirban RK, Khatri P, Beniwal S, Kumar HS, et al. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study. J Cancer Res Ther. 2020;16(3):559-64. DOI: https://doi.org/10.4103/jcrt.JCRT_702_18
Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36-51. DOI: https://doi.org/10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I
Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993;35(4):409-12. DOI: https://doi.org/10.1111/j.1365-2125.1993.tb04158.x
Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163-72. DOI: https://doi.org/10.1124/pr.57.2.3
Yang Z, Mo J, Li W, Zhao Z, Mei S. Methotrexate polyglutamates. Expert Rev Clin Pharmacol. 2024;17(11):1025-37. DOI: https://doi.org/10.1080/17512433.2024.2416674
Song Z, Hu Y, Liu S, Jiang D, Yi Z, Benjamin MM, et al. Genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: A systematic review and meta-analysis. Front Pharmacol. 2021;12:757464. DOI: https://doi.org/10.3389/fphar.2021.757464
Dhar H, Hamdi I, Rathi B. Methotrexate Treatment of Ectopic Pregnancy: Experience at Nizwa Hospital. Oman Med J. 2011;26(2):94-8. DOI: https://doi.org/10.5001/omj.2011.24
Yamamoto T, Shikano K, Nanki T. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in rheumatoid arthritis. Sci Rep. 2016;6:35615. DOI: https://doi.org/10.1038/srep35615
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of rituximab in rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81. DOI: https://doi.org/10.1056/NEJMoa032534
O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr, Ranganath VK, et al. Validation of methotrexate as first-line therapy in rheumatoid arthritis. Arthritis Rheum. 2007;56(4):1219-23.
Vermeer E, Hebing RCF, van de Meeberg MM, et al. Oral versus subcutaneous methotrexate in immune-mediated inflammatory disorders: an update. Curr Rheumatol Rep. 2023;25:276-84. DOI: https://doi.org/10.1007/s11926-023-01116-7
Lima A, Bernardes M, Azevedo R, Medeiros R, Seabra V. Pharmacogenomics of the methotrexate membrane transport pathway. Int J Mol Sci. 2015;16(6):13760-80. DOI: https://doi.org/10.3390/ijms160613760
VanWert AL, Sweet DH. Impaired clearance of methotrexate in organic anion transporter 3 knockout mice. Pharm Res. 2008;25(2):453-62. DOI: https://doi.org/10.1007/s11095-007-9407-0
Bannwarth B, Péhourcq F, Lequen L. Pharmacokinetics of methotrexate in rheumatoid arthritis. Therapie. 1997;52(2):129-32.
Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3299-308. DOI: https://doi.org/10.1002/art.24034
Torres RP, Santos FP, Branco JC. Methotrexate: Implications of pharmacogenetics in rheumatoid arthritis. ARP Rheumatol. 2022;1(3):225-9.
Downloads
Published
How to Cite
Issue
Section
